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October 23, 2012:1710–4A mitral valve replacement and tricuspid valve repair were per-
formed. The patient had an uneventful recovery.
Discussion. Thrombosis of a mechanical valve is a potentially
atal complication. With warfarin anticoagulation, the incidence of
alve thrombosis is low (1). In both presented cases, patients were
anticoagulated with warfarin and had never experienced throm-
botic or bleeding events. One month after being switched from
warfarin to dabigatran both patients became symptomatic and
were subsequently diagnosed with thrombosis. While a causal link
is not certain, the temporal association is highly suggestive.
Dabigatran is one of several novel oral anticoagulants evaluated
as a substitute for warfarin. Regulatory approval was based on the
pivotal RE-L-Y (Randomized Evaluation of Long-Term Antico-
agulation Therapy) trial, which compared dabigatran to warfarin
for the treatment of nonvalvular AF (2). This study demonstrated
equivalent freedom from thrombotic events with fewer hemor-
rhagic events for low-dose dabigatran (110 mg, twice daily) and
superior freedom from thrombotic events with equivalent bleeding
with higher dose dabigatran (150 mg, twice daily). Additional
advantages of dabigatran include stable dosing, no requirement for
monitoring, and fewer interactions.
In vitro and animal studies suggest that Dabigatran for mechan-
ical valve anticoagulation may be a potential therapeutic avenue
(3,4). Recently, enoxaparin was compared to dabigatran for anti-
coagulation of mechanical aortic valves. Dabigatran was found to
reduce thrombus burden with a dose of 20 mg/kg twice daily,
corresponding to an aPTT of 2 to 2.5 times normal in the porcine
model. This question is now being addressed with a phase II
clinical trial, RE-ALIGN (NCT01452347), which utilizes doses
ranging from 150 to 330 mg twice daily, adjusted based on renal
function and results of the Hemoclot assay.
The failure of 1 patient to achieve adequate anticoagulation
Figure 2 Thrombosed Aortic Valve Prosthesis
Surgical photograph demonstrating the intraoperative appearance of the pros-
thetic aortic valve. Significant thrombus was observed on both the ventricular
and aortic sides of the prosthesis.despite a “highdose” and that a second experienced valve throm-bosis despite therapeutic aPTT levels highlights the importance of
medication testing for a specific indication. Furthermore, AF may
represent a lesser thrombotic risk than a mechanical prosthesis,
particularly mitral. While there is a wealth of data and clinical
experience on dosing and therapeutic response to warfarin in this
context, these data are unavailable for dabigatran.
Off-label use of novel drugs can jeopardize potential future
applications in new disease contexts and should be avoided until
data from well-designed clinical studies is available. Novel oral
anticoagulants hold tremendous promise for mechanical valve
anticoagulation. However, there is a need for dose-finding studies
and clinical trials to demonstrate safety and efficacy in this setting.
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Letters to the Editor
18F-Fluoride Imaging
or Atherosclerosis
We read with great interest the article on coronary artery calcifi-
cation by Dweck et al. (1) recently published in the Journal.
Although the authors claimed that this communication was the
first on this topic in the literature, we would direct the readership
to our original article, “Detection and global quantification of
cardiovascular molecular calcification by fluoro18-fluoride positron
emission tomography/computed tomography—a novel concept”
(2) and accompanying editorial, “Assessing global cardiovascular
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come a clinical reality and a challenge to CT calcification scoring?”
(3), published earlier on the same topic.
In addition, we take issue with a number of points made by the
uthors (1). Although we agree with them that it is feasible to
detect cardiac calcifications using 18F–sodium fluoride far in
advance of visualizing this phenomenon with x-ray computed
tomography (CT), attempts to image coronary artery calcification
by visualizing the artery on CT scan are challenging for a variety of
reasons. First, it is extremely difficult to localize the coronary
arteries without the assistance of contrast dye. The administration
of x-ray contrast agent is not practical for screening of individuals
at risk, given the potential toxicity of these agents. As noted by the
investigators (1), it is necessary to assign regions of interest on
clearly visualized calcifications on CT scan for detecting the
ongoing calcification. Because the power of 18F–sodium fluoride
technology lies in its early ability to detect molecular calcification
in advance of structural abnormalities observed on CT scan,
assigning a region of interest based on coronary artery calcification
is not feasible in early disease in younger patients. Second, the
authors (1) failed to address the need for partial volume correction,
which is of importance in such small structures as coronary arteries
because loss of signal or spillover from adjacent signal may occur
when a relatively small region of interest is evaluated. Particularly,
motion artifacts due to the cardiac cycle further degrades the
spatial resolution and necessitates partial volume correction. Third,
the blood pool correction for background activity of tracer adds
further complexity and potential error.
We believe that a methodology independent of recognition of
vascular distribution, a global assessment, will be of great value in
detecting early disease before calcification is apparent on electron
beam CT imaging. The methodology that we presented in
publications predating the recent article by Dweck et al. (1)
describes a global assessment of molecular calcification detected
with 18F–sodium fluoride. Although the methodology described in
this article (1) appears to be reproducible by the investigators involved,
this may not be the case for inexperienced practitioners. A global
assessment of cardiac calcification obviates the need for partial volume
correction and therefore is essential in assessing overall calcification in
the heart. In addition, a global approach allows for delayed imaging of
2 to 3 h after the administration of sodium fluoride, which would
obviate the need for blood pool correction.
There is certainly a dire need for visualizing atherosclerotic
disease in early stages and 18F–sodium fluoride imaging may
realize this objective. Prospective, randomized clinical trials are
needed to determine the feasibility and clinical benefit of 18F–
odium fluoride imaging for early atherosclerotic disease.
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Reply
We thank Dr. Mohler and colleagues for their interest in our study
and for their communication. We agree that prospective random-
ized clinical trials are now required to assess the clinical benefit of
cardiovascular 18F–sodium fluoride (18F-NaF) scanning.
Our paper was the first prospective description of 18F-NaF
uptake in the coronary arteries of patients specifically studied to
assess the heart (1). The highlighted paper by Behshti et al. (2)
described 18F-NaF activity within the heart in a small retrospective
ohort of patients with cancer that did not localize 18F-NaF uptake to
he coronary arteries. Their approach was to draw ellipsoid regions of
nterest around the cardiac silhouette on noncontrast axial images.We
reviously demonstrated that 18F-NaF activity also occurs within
oncoronary structures in the heart, most notably the aortic valve and
itral valve annulus (1). As such, cardiac and coronary 18F-NaF
uptake cannot be considered synonymous.
There is the further question of whether it is possible to measure
18F-NaF uptake only in the coronary vessels. We demonstrated
hat this is the case and is evidenced in the images and the excellent
easures of reproducibility we obtained and reported in our paper.
ost of our population with aortic stenosis had high calcium
cores, and so it was readily possible to determine the course of the
oronary arteries on both the electrocardiogram-gated and non-
ated scans. We accept that in patients with less advanced disease,
omputed tomography coronary angiography will be required to
etter visualize the lesions displaying increased 18F-NaF uptake.
Indeed we are currently conducting such a study and can localize
18F-NaF uptake not only to individual coronary arteries but also
ndividual plaques and their components.
We recognize that the issue of partial volume averaging is
mportant in positron emission tomography (PET) imaging.
owever, the spatial resolution of PET is approximately 3 mm.
e are interested in localizing 18F-NaF activity to individual
laques, which are commonly 20 to 30 mm long in vessels with a
iameter of 3 to 4 mm. Therefore, our approach is well within the
patial resolution of PET, especially given the very high signal-to-
ackground ratio observed with 18F-NaF in the heart. Quantifying
he maximum uptake value is straightforward as reflected by our
xcellent measures of reproducibility, and we are confident that our
pproach will be reproduced by other groups. Indeed, several
tudies have confirmed the feasibility of this approach using
18F-fluorodeoxyglucose in the coronary arteries (2,3).
Given the above, we do not believe that a volume of interest
approach to the measurement of 18F-NaF uptake in the heart is
warranted. This would result in coronary arterial 18F-NaF mea-
sures being conflated with valvular uptake. In addition, that
approach would fail to harness the high sensitivity and spatial
